

FLOW SHEET, Year one Regime B

Name, personal identifier							Starting dose		Dose-Level -1		Dose-Level -2		Dose Level -3	
			Epirubicin (mg/m²)				75		60		50		Discontinue	
			Cyclophosphamide (mg/m²)			600		500		400		Discontinue		
			Capecitabine (mg/m²) 900 x 2 700 x 2 500 x 2 300 x 2											
Hight (cm): Weight (kg):		Surface (m²): Red			Reduc	uce starting dose-level in the presence of severe co-morbidity								
Year Week no.		Week no.	0	1	2	3	4	5	6	7	8	9	10	11
Day, month														
			1. cycle			2. cycle			3. cycle			4. cycle		
Epirubicin (mg)														
Cyclophosphamide (mg)														
Capecitabine (mg days 1-14)			ı						ı			ı		
Growth factor support 0=no, 1=yes														
Pembrolizumab (mg)														
Ovarian function suppression 0=no, 1=yes														
Zoledronic acid (mg)														
Hematological toxicity If absolute neutrophil count (ANC) < 1.0×10^9 /L on a day of planned treatment postpone treatment until ANC ≥1.0 and if ANC 0.5-0.9 on day one keep starting dose. On the second occasion reduce by one level. If ANC<0.5 postpone until ANC≥1.0 and reduce by one dose level. If platelets < 100×10^9 /L on a day of planned treatment postpone treatment until platelets ≥100 and keep dose level if platelets 50-99 (reduce by one dose level on second occasion) and if platelets <50 reduce by one dose level.														
Enter on day 1	Neutrophils (x10 ⁹ /L)												
	Leucocytes (x10 ⁹ /L)													
	Haemoglobine (mmol/L)													
Thrombocytes (x10 ⁹ /L)														
Non-hematolo	ogical toxicity	Grade 3 and 4 sl	hould re	esult in	dose re	duction								
Febrile neutropenia 0 -		0 – 4												
Mouth or throat sores		0 – 2												
Nausea		0 – 2												
Vomiting		0 – 4												
Diarrhea		0 – 4												
Rash 0 – 2		0-2												
Hand-foot syndrome 0 – 2														
Myalgia 0 – 2		0-2												
Arthralgia		0 – 2												
Numbness & tingling 0 – 4		0 – 4												
Cooling gloves	used	0=no, 1=yes												
Fatigue		0-2												
Missed expect	ed menses	0=no, 1=yes												
Other, add text		0 – 4												
Other, add text 0 – 4														

In case of any grade 3 or 4 toxicity make a record in the study specific CRF or eJournal of day of start and resolution as well as relation to the study drugs (related, possible related, or not related).



FLOW SHEET, Year one Regime B

Name, personal identifier							g dose	Dose-Level -1		Dose-Level -2		Dose Level -3		
			Paclitaxel (mg/m²), A +C			80		65		50		Discontinue		
		Carboplatin (AUC), C				5		4		3		Discontinue		
Height (cm): Weight (kg):		Surface (m²):			Reduc	Reduce starting dose-level in the presence of severe co-morb							rbidity	
Year	Week no.	12	13	14	15	16	17	18	19	20	21	22	23	
Day, month														
			5. cycle			6. cycle			7. cycle			8. cycle		
Paclitaxel (mg),	, iv. day 1+8+15													
Carboplatin (mg	g), iv. day 1													
Growth factor support 0=no, 1=yes														
Pembrolizumab (mg)														
Ovarian function suppression 0=no, 1=yes														
Zoledronic acid (mg)														
Hematological toxicity If absolute neutroph ≥1.0 and add growth factor support. On the						•	•			•				
	pone treatment until platele				-		•	natelets	\ 100	X 10 /L	on a u	ay or pr	aiiiieu	
	Neutrophils (x10 ⁹ /L)													
_	Leucocytes (x10 ⁹ /L)													
-	Hemoglobin (mmol/L)													
<u> </u>	Thrombocytes (x10 ⁹ /L)													
		•												
Renal function														
On day 1 GFR ml/min														
Non-hematological toxicity Grade 3 and 4 st		hould re	sult in	lose rec										
Febrile neutropenia 0 – 4			Juit III (1036 166	uction					1				
Febrile neutrop	penia 0 – 4		Suit III (1036 166	uction									
Febrile neutrop Mouth or throa				1036 166	luction									
			July III		duction									
Mouth or throa	at sores 0 – 2			3030 100	duction									
Mouth or throa	0 – 2 0 – 2				luction									
Mouth or throat Nausea Vomiting	0-2 0-2 0-4				luction									
Mouth or throat Nausea Vomiting Diarrhea	0-2 0-2 0-4 0-4 0-2				duction									
Mouth or throat Nausea Vomiting Diarrhea Rash	0-2 0-2 0-4 0-4 0-2			1000	duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$			1000	duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$			1000 100	duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia Arthralgia	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$				duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia Arthralgia Numbness & til	$ \begin{array}{ccccccccccccccccccccccccccccccccccc$				duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia Arthralgia Numbness & tit Cooling gloves					duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia Arthralgia Numbness & till Cooling gloves Fatigue					duction									
Mouth or throat Nausea Vomiting Diarrhea Rash Hand-foot synd Myalgia Arthralgia Numbness & tin Cooling gloves Fatigue Missed expecte	$\begin{array}{cccccccccccccccccccccccccccccccccccc$				duction									

In case of any grade 3 or 4 toxicity make a record in the study specific CRF or eJournal of day of start and resolution as well as relation to the study drugs (related, possible related, or not related).